Amgen has completed its acquisition of worldwide rights to Otezla (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla, along with certain related assets and liabilities, was acquired from Celgene Corp. for $13.4 billion in cash, in connection with its previously announced merger with Bristol-Myers Squibb Co., which was completed on Nov. 20.   Otezla is an important treatment in the post-topical, pre-biologic segment in its...